Stroke Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 22 years or older
- People who are showing sudden neurological symptoms (such as weakness, speech problems, or facial drooping) that are suspected to be a stroke, with symptoms starting within the last 24 hours
- People whose participation in the scan would not cause any delay to their standard stroke treatment
- People who are scheduled to have a CT or MRI brain scan as part of their normal medical care
- People whose head size is suitable for use with the EMVision emu™ Brain Scanner device
Who may not be able to join:
- People who have already received treatment for the suspected stroke (such as clot-dissolving medication) before their first CT/MRI scan or the study device scan
- People who were already admitted to hospital for a neurological condition before the suspected stroke occurred
- People who were already in an intensive care unit before the suspected stroke occurred
- People who cannot have brain imaging for medical reasons, such as an allergy to contrast dye or another condition that prevents CT, MRI, or similar scans
- People who have an implanted electrical stimulation device in the head or neck area
- People who have any metal implants inside or around the skull (note: metal items further from the scan area, such as dental implants or nasal piercings, are generally acceptable — confirm with trial site)
- People who have an intracranial pressure monitor or similar device in place that could interfere with fitting the study scanner
- People who are unable to wear the study device, for example due to scalp wounds, a recent head injury, previous brain surgery, or a neck injury
- People who are unable to remain still for the duration of the scan
- People who are pregnant or breastfeeding
- People who have any other condition or symptom that the treating doctor considers would make participation unsuitable
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Reade De Leacy, MBBS(Hons) FRANZCR, Associate Professor of Neurosurgery and Radiology Director of Neurointerventional Spine Site Director Cerebrovascular Services Mount Sinai Queens Co-director Neuroendovascular Surgery Fellowship Department of Neurosurgery Mount Sinai Health System
Phone: 61 (0) 490 109 797
Australian sites
0428 292 184
03 9342 4413
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
2 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Demonstrate haemorrhage detection sensitivity >80% and specificity >80%
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.